Which GLP-1 Is Best for Weight Loss? Comparing Wegovy, Zepbound, and Saxenda

Which GLP-1 Is Best for Weight Loss?

The clinical answer is tirzepatide (Zepbound), which produced ~22.5% body weight loss at its highest dose. Semaglutide (Wegovy) trails at ~15%. Liraglutide (Saxenda) at ~8%.

The practical answer is different. The GLP-1 that produces the most weight loss for you is whichever one your insurance formulary covers, your pharmacy has in stock, and your gut can tolerate past week six. Trial data ranks these drugs on efficacy. Your experience will be shaped more by prior authorization timelines and copay tiers. That gap -- between what the data says works best and what you can actually fill at the pharmacy counter -- is where most of the real decision-making happens.

For a side-by-side interactive comparison, visit our GLP-1 comparison tool.

Head-to-Head: Clinical Trial Data for Weight Loss

Tirzepatide (Zepbound) -- SURMOUNT Trial Program

Tirzepatide is a dual GLP-1/GIP receptor agonist from Eli Lilly, approved for chronic weight management as Zepbound in November 2023.

SURMOUNT-1 (2022): 2,539 adults with BMI 30+ (or 27+ with a weight-related comorbidity), no diabetes.

• 5mg dose: 15.0% average body weight reduction
• 10mg dose: 19.5% average body weight reduction
• 15mg dose: 22.5% average body weight reduction
• Placebo: 3.1%
• Duration: 72 weeks
• Over one-third on the 15mg dose lost more than 25% of body weight

SURMOUNT-2 (2023): Tirzepatide in adults with obesity/overweight and type 2 diabetes.

• 10mg dose: 12.8% average weight reduction
• 15mg dose: 14.7% average weight reduction
• Weight loss runs lower in patients with type 2 diabetes across all GLP-1 medications

Semaglutide (Wegovy) -- STEP Trial Program

Semaglutide 2.4mg is a GLP-1 receptor agonist from Novo Nordisk. Wegovy was approved for chronic weight management in June 2021.

STEP 1 (2021): 1,961 adults with obesity or overweight with comorbidities, no diabetes.

• 2.4mg dose: 14.9% average body weight reduction
• Placebo: 2.4%
• Duration: 68 weeks
• About one-third of participants lost more than 20% of body weight

STEP 8 (2022): Direct comparison -- semaglutide 2.4mg vs. liraglutide 3.0mg.

• Semaglutide 2.4mg: 15.8% body weight reduction
• Liraglutide 3.0mg: 6.4% body weight reduction
• Semaglutide beat liraglutide on every weight-related endpoint

SELECT Trial (2023): 20% reduction in major adverse cardiovascular events (heart attack, stroke, CV death) in overweight/obese adults without diabetes. This earned Wegovy its expanded cardiovascular risk reduction indication.

Liraglutide (Saxenda) -- SCALE Trial Program

Liraglutide 3.0mg, also Novo Nordisk, approved for weight management in 2014. The oldest agent here.

SCALE Obesity and Prediabetes (2015): 3,731 adults with obesity or overweight with comorbidities.

• 3.0mg dose: 8.0% average body weight reduction
• Placebo: 2.6%
• Duration: 56 weeks

Saxenda produces less weight loss than the newer drugs. It has over a decade of real-world safety data, which neither Wegovy nor Zepbound can claim yet.

The Complete Comparison Table

Factor	Zepbound (Tirzepatide)	Wegovy (Semaglutide)	Saxenda (Liraglutide)
Avg. Weight Loss	~22.5% (15mg)	~15% (2.4mg)	~8% (3.0mg)
Drug Class	Dual GLP-1/GIP agonist	GLP-1 agonist	GLP-1 agonist
Dosing	Once weekly	Once weekly	Once daily
Dose Range	2.5mg - 15mg	0.25mg - 2.4mg	0.6mg - 3.0mg
Titration Period	~20 weeks to max dose	~16 weeks to max dose	~5 weeks to max dose
Administration	Subcutaneous injection	Subcutaneous injection	Subcutaneous injection
CV Outcomes Data	Pending (SURPASS-CVOT)	Yes -- 20% MACE reduction (SELECT)	No dedicated CV outcomes trial
List Price (monthly)	~$1,060	~$1,350	~$1,350
Manufacturer Savings	Eli Lilly savings card available	Novo Nordisk savings program	Novo Nordisk savings program
FDA Approval Year	2023	2021	2014
Pediatric Indication	Under study	Ages 12+ approved	Ages 12+ approved

Note on pricing: List prices fluctuate. Actual out-of-pocket costs depend on insurance coverage, manufacturer savings programs, and pharmacy. See our GLP-1 cost guide for current pricing.

What Actually Determines Which GLP-1 You Get

1. Insurance Coverage and Cost

Coverage drives prescribing more than efficacy data does. In practice, your insurer's formulary often makes the decision for you -- a dynamic that deserves more scrutiny than it gets.

• Commercial insurance: Improving but inconsistent. Many plans cover Wegovy or Zepbound but require prior authorization, step therapy (trying a cheaper option first), or documented failure of lifestyle intervention.
• Medicare Part D: As of 2026, Medicare covers anti-obesity medications for certain indications following legislative changes. Plan-level specifics vary.
• Medicaid: State-dependent. Some states cover GLP-1s for obesity. Others restrict coverage to diabetes-only indications.
• Cash pay: $1,000-$1,350/month without insurance. Manufacturer savings programs reduce this for eligible patients, but eligibility rules change frequently.

If your plan covers Wegovy but not Zepbound, 15% average weight loss is still a strong clinical outcome. Do not wait months fighting a denial when a covered drug is available now.

Explore our GLP-1 insurance coverage guide for plan-specific details and prior authorization strategies.

2. Side Effect Tolerance

GLP-1 medications share a GI side effect profile. Severity differs by drug and by person.

Side Effect	Zepbound (15mg)	Wegovy (2.4mg)	Saxenda (3.0mg)
Nausea	24-33%	44%	39%
Diarrhea	17-23%	30%	21%
Vomiting	9-13%	24%	16%
Constipation	11-17%	24%	19%
Discontinuation due to AEs	4.3-7.1%	6.8%	9.8%

The tradeoff with tirzepatide is real: it produces the most weight loss but also activates two receptor pathways. Zepbound's GI rates look lower than Wegovy's in the table, but these come from separate trials with different populations, not a head-to-head comparison. Wegovy reported higher nausea and vomiting rates across STEP trials. Saxenda requires daily injections and had the highest discontinuation rate.

Side effects peak during dose escalation. Most patients tolerate them better after the first 8-12 weeks. If one GLP-1 was intolerable, switching to another often produces a different experience.

3. Injection Frequency

• Once weekly (Zepbound, Wegovy): Preferred by most patients. Better adherence.
• Once daily (Saxenda): Some patients prefer the control daily dosing offers, particularly the ability to pause or reduce dose quickly when side effects flare.

4. Diabetes Comorbidity

A type 2 diabetes diagnosis changes the calculus in two ways: drug selection and insurance access.

• Tirzepatide (as Mounjaro) delivers the strongest A1C reduction (~2.4% at highest dose).
• Semaglutide (as Ozempic) is well-established for diabetes with strong cardiovascular data.
• Insurance plans more readily cover the diabetes-branded versions (Mounjaro, Ozempic) than the weight-specific brands (Zepbound, Wegovy). Same molecules, different brand names, different formulary placement.

Providers often prescribe the diabetes-indication version to patients with both conditions, capturing glycemic control and weight loss under a single coverage pathway.

5. Cardiovascular History

If you have established cardiovascular disease or elevated CV risk, Wegovy has the strongest evidence right now. The SELECT trial showed a 20% reduction in major cardiovascular events, independent of weight loss. Tirzepatide's CV outcomes trial (SURPASS-CVOT) is still underway.

6. Long-Term Sustainability

Weight regain after discontinuation is the hard truth of this drug class. The STEP 1 extension trial found participants regained roughly two-thirds of lost weight within one year of stopping semaglutide. These are not short-term medications. The GLP-1 that works best for you is the one you can keep taking -- factoring in cost trajectory, insurance stability, tolerability, and treatment burden over years.

Decision Framework: Choosing Your GLP-1

Use this as a starting point with your provider:

If your priority is...	Consider starting with...	Why
Maximum weight loss	Zepbound (tirzepatide)	Highest efficacy in trials (~22.5%)
Proven cardiovascular benefit	Wegovy (semaglutide)	SELECT trial data; FDA-approved for CV risk reduction
Longest safety track record	Saxenda (liraglutide)	FDA-approved since 2014; 10+ years of real-world data
Weekly convenience	Zepbound or Wegovy	Both are once-weekly injections
Insurance is the deciding factor	Whichever is covered	Any FDA-approved GLP-1 produces meaningful weight loss
Diabetes + weight management	Mounjaro or Ozempic	Diabetes indication improves coverage; dual benefit
Lower GI side effects	Zepbound (tirzepatide)	Lower reported GI rates relative to efficacy
Adolescent patient (12+)	Wegovy	FDA-approved for ages 12 and older

Off-Label and Compounded Options

Some patients use diabetes-indicated GLP-1s (Ozempic, Mounjaro) off-label for weight loss. The active ingredients are identical to Wegovy and Zepbound, but insurance and regulatory implications differ. Compounded semaglutide and tirzepatide products are available through certain pharmacies. These carry distinct quality and safety considerations -- they are not FDA-approved finished products.

For a detailed analysis, visit our compounded GLP-1 guide.

What Clinical Trials Do Not Show You

Trial populations are selected and monitored in ways that do not reflect normal healthcare.

• Adherence: Trial participants get structured support. Real-world adherence to injectables drops substantially, especially after the first year.
• Lifestyle modification: Every trial required diet and exercise changes alongside the drug. The medication alone accounts for a portion of total weight lost, not all of it.
• Response variability: Some people lose 30%+ of body weight. Others lose 5%. Genetic variation in GLP-1 receptor sensitivity is an active research area with no clinical test available yet.
• Duration: Pivotal trials ran 68-72 weeks. Long-term data beyond 3 years is still accumulating for Wegovy and does not yet exist for Zepbound.

When This Actually Matters

• You have commercial insurance and your plan covers one GLP-1 but not another. Start with what is covered. Do not delay treatment chasing a prior auth for a marginally better option.
• You have type 2 diabetes and obesity. The diabetes-branded version (Mounjaro or Ozempic) may be easier to get covered and treats both conditions.
• You have cardiovascular disease. Wegovy is the only GLP-1 with a completed CV outcomes trial showing reduced heart attacks and strokes.
• You tried one GLP-1 and could not tolerate the side effects. Switching drug class (GLP-1-only to dual GLP-1/GIP, or vice versa) often changes the tolerability picture.
• You are paying cash. Zepbound's list price is lower than Wegovy's (~$1,060 vs. ~$1,350/month), and it produces more weight loss. The cost-effectiveness math favors tirzepatide for self-pay patients.
• You are uninsured with BMI-only qualification (no diabetes). Access is hardest here. Manufacturer savings programs, state assistance, and compounded options may be the only affordable paths.

---

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting, stopping, or changing any medication.